Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors - Top-Institutions - MDSpire

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

  • By

  • Charissa A. C. Jessurun

  • Francesca Siddi

  • Noah L.A. Nawabi

  • Alexander F. C. Hulsbergen

  • Yu Tung Lo

  • Rohan Jha

  • Timothy R. Smith

  • Marike L. D. Broekman

  • February 7, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Immunotherapy
    • Medical Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Immunotherapy
    • Radiation Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Immunotherapy
    • Surgical Oncology

  • #4

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Immunotherapy

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neuro-oncology
    • Immunotherapy
    • Neurosurgery

Original Source(s)

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

  • by Charissa A. C. Jessurun, Francesca Siddi, Noah L.A. Nawabi, Alexander F. C. Hulsbergen, Yu Tung Lo, Rohan Jha, Timothy R. Smith, Marike L. D. Broekman

  • February 7, 2025

Related Content

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

An ASCO preview: What to watch for at cancer research’s big meeting